β细胞的免疫原性用于 1 型糖尿病的自体移植。

Immunogenicity of β-cells for autologous transplantation in type 1 diabetes.

机构信息

Islet Transplantation Laboratory, Division of Transplantation, Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Thier 825, Boston, MA 02114, United States.

出版信息

Pharmacol Res. 2015 Aug;98:60-8. doi: 10.1016/j.phrs.2015.03.003. Epub 2015 Mar 20.

DOI:10.1016/j.phrs.2015.03.003

PMID:25801943

Abstract

The success of clinical islet transplantation calls for a broader application of this curative treatment for type 1 diabetes mellitus. The toxicity of immunosuppression, limited organ donor supply and high procedural costs are deterrents to expand this therapy to patients with uncomplicated diabetes. The use of pancreatic β-cell like cells derived from the patient's own induced pluripotent cells (iPSC) holds potential to overcome these barriers. In this review, we discuss the practicality of this regenerative medicine approach and existing evidence regarding the true immunogenicity of iPSC derived cells.

摘要

临床胰岛移植的成功呼吁更广泛地将这种治疗方法应用于 1 型糖尿病。免疫抑制的毒性、有限的器官供体供应和高程序成本阻碍了将这种治疗方法扩展到无并发症的糖尿病患者。使用源自患者自身诱导多能干细胞（iPSC）的胰腺β细胞样细胞具有克服这些障碍的潜力。在这篇综述中，我们讨论了这种再生医学方法的实用性以及关于 iPSC 衍生细胞真正免疫原性的现有证据。